Chronic hepatitis C treatment in näive patients
Hepatitis C (HCV) is a major public health problem worldwide and it is considered that there are about 180 millions of infected people. The natural history of hepatitis C shows that, of those individuals affected by a primo-infection, 55 to 95% evolve into chronicity. The objective of treatment for...
Main Author: | Jorge Daruich |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-01-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119317272 |
Similar Items
-
New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C
by: Markus Cornberg, et al.
Published: (2005-07-01) -
Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01) -
Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C
by: Hamid Kalantari, et al.
Published: (2007-08-01) -
Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient
by: Emanuele Durante-Mangoni, et al.
Published: (2011-04-01) -
An open, non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2b pegylated interferon PEG-Heberon® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients
by: Marlen I Castellanos-Fernández, et al.